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Abstract
Introduction: The risks of cardiovascular diseases, the 
leading cause of death in the world, can be reduced by 
diet. Cowpea protein has been shown to significantly re-
duce total cholesterol, LDL-cholesterol, and liver stea-
tosis in hamsters.
Objective: The objective of this proof-of-concept 
study was to verify whether the consumption of cowpea 
protein improves lipid profile and biomarkers of in-
flammation and endothelial dysfunction in adults with 
moderate hypercholesterolemia. 
Methods: In a randomized, double-blind, crossover 
design, 38 hypercholesterolemic subjects (LDL-choles-
terol = 182.5 ± 2.7 mg/dL) consumed 25 g/day of cowpea 
protein isolate or 25 g/day of casein (control group) for 
6 weeks each, separated by a 4-week washout interval. 
Fasting blood samples were collected at baseline and 
at the end of each diet period. Lipids (total choleste-
rol, LDL-cholesterol, triglycerides, HDL-cholesterol) 
were determined by enzymatic methods, apolipoprote-
ins (apoA-I and apoB) by standardized immunoassays, 
inflammatory biomarkers (C-reactive protein) by tur-
bidimetry, and biomarkers of endothelial dysfunction 
(intercellular adhesion molecule 1 and vascular cell 
adhesion molecule 1) by enzyme-linked immunosorbent 
assays.
Results and discussion: Consumption of cowpea pro-
tein significantly reduced total cholesterol (12 %), LDL-
cholesterol (18.9  %), nonHDL-cholesterol (16  %) and 
apoB (14 %), and increased HDL-cholesterol (+2.7 %). 
No significant differences between treatment groups 
were observed for any of the serum inflammatory or 
endothelial dysfunction biomarkers.
Conclusion: The present findings demonstrated the 
favorable effect of cowpea protein consumption on 
PROTEÍNA CAUPÍ REDUCE LAS 
CONCENTRACIONES DE LDL-COLESTEROL 
Y APOLIPOPROTEÍNA B, PERO NO MEJORA 
BIOMARCADORES INFLAMATORIOS Y 
DISFUNCIÓN ENDOTELIAL EN ADULTOS CON 
HIPERCOLESTEROLEMIA MODERADA
Resumen
Introducción: Los riesgos de las enfermedades car-
diovasculares, la principal causa de muerte en el mun-
do, pueden ser reducidos con la dieta. Proteína caupí 
en hámsters redujo el colesterol total, LDL-colesterol, 
así como la esteatosis hepática de manera significativa.
Objetivo: Este estudio de prueba de concepto fue veri-
ficar si el consumo de proteína de frijol mejora el perfil 
de lípidos y actúa sobre los biomarcadores de inflama-
ción y disfunción endotelial en pacientes con hipercoles-
terolemia moderada.
Métodos: En un diseño aleatorio doble ciego cruza-
do, 38 sujetos con hipercolesterolemia (colesterol-LDL 
= 182,5 ± 2,7 mg/dL) consumieron 25 g / día de aisla-
do de proteína de frijol o 25 g / día de caseína (grupo 
control) durante seis semanas cada uno, y un intervalo 
de lavado de cuatro semanas Se recogieron muestras de 
sangre en ayunas al comienzo y al final de cada perío-
do de dieta. Los lípidos (colesterol total, LDL-coleste-
rol, triglicéridos, HDL-colesterol) se determinaron por 
métodos enzimáticos, apolipoproteínas (apoA-I y apoB) 
por inmunoensayos normalizados, biomarcadores de in-
flamación (proteína C reactiva) por turbidimetría y los 
biomarcadores de disfunción endotelial (molecule-1 de 
adhesión intercelular y de molécula-1 de adhesión celu-
lar vascular) por técnicas de ensayo de inmunoabsor-
ción ligados a enzimas. 
Resultados y discusión: El consumo de proteínas cau-
pí redujo significativamente el colesterol total (12%), el 
colesterol LDL (18,9%), colesterol no HDL (16%), apoB 
(14%), y aumentó el colesterol HDL (2,7%). No se ob-
servaron diferencias significativas relacionadas con el 
grupo de tratamiento para cualquiera de los biomarca-
dores inflamatorios y de disfunción endotelial.
Conclusión: Los presentes hallazgos demostraron 
el efecto favorable del consumo de proteína caupí en 
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Abbreviations
CVD: cardiovascular disease.
LDL-C: low-density lipoprotein cholesterol.
TNFα: tumor necrosis factor α.
IL1: interleukin 1.
CRP: C-reactive protein.
VCAM1: vascular cell adhesion molecule 1.
ICAM1: intercellular adhesion molecule 1.
CHD: coronary heart disease.
CPI: cowpea protein isolate.
BMI: body mass index.
HDL-C: high-density lipoprotein cholesterol.
NonHDL-C: nonHDL cholesterol.
ApoA-I: apolipoprotein AI.
ApoB: apolipoprotein B.
SEM: standard error of the mean.
kg: kilogram.
cm: centimeter.
kJ: kilojoule.
g: gram.
Introduction
Cardiovascular diseases (CVD) are the leading cau-
se of death and disability in the world1. In the United 
States, CVD account for 31.9% of all deaths1. A large 
body of evidence has established a direct and causal 
association between elevated blood cholesterol and 
increased CVD risk2-4. There is undisputable evidence 
that lowering cholesterol reduces morbidity and mor-
tality due to CVD. The impact on CVD risk appears to 
be similar whether low-density lipoprotein cholesterol 
(LDL-C) is reduced by dietary or surgical intervention 
(ileal bypass), or by medications2, 5.
Atherosclerosis is a multifactorial disease and 
etiological factors include low-grade subclinical in-
flammation and endothelial dysfunction6. Subclinical 
inflammation plays an important systemic role in the 
development of CVD. Inflammatory biomarkers such 
as tumor necrosis factor α (TNFα), interleukin 1 (IL1), 
and C-reactive protein (CRP) have been associated 
with the atherosclerotic process7. All of these factors 
induce the expression of cell adhesion molecules such 
as vascular cell adhesion molecule 1 (VCAM1) and 
intercellular adhesion molecule 1 (ICAM1) which, in 
turn, mediate the adhesion of leukocytes to the vascu-
lar endothelium8. 
Diet is an important modifiable risk factor for many 
types of heart disease5. Legume consumption has been 
associated with a lower risk of coronary heart disea-
se (CHD) in observational epidemiological studies, 
and has been shown to decrease total cholesterol and 
LDL-C in clinical trials9-11. However, most studies eva-
luating the hypocholesterolemic effects of legume con-
sumption specifically examined soybean rather than 
the many non-soy legumes which are more common-
ly consumed in Western countries12. In this respect, a 
strong hypocholesterolemic effect of cowpea protein 
has been demonstrated in a recent animal study13.
The aim of this proof-of-concept study was to eva-
luate the effect of consumption of a ready-to-drink 
product made from cowpea protein on serum lipids 
and apolipoproteins in moderately hypercholesterole-
mic adults. The effect of ingestion of this protein on 
biomarkers of systemic inflammation (CRP) and en-
dothelial dysfunction (VCAM1 and ICAM1) was also 
investigated.
Materials and methods
Study design
Forty-four eligible men and women were randomly 
assigned to one of two dietary treatments in a dou-
ble-blind, placebo-controlled, crossover study. Treat-
ment consisted of the consumption of either 25 g of 
a ready-to-drink product made from cowpea protein 
isolate (CPI) or a comparative control (25 g of casein). 
The test foods were offered in the form of a shake con-
sumed daily for 6 weeks. After a 4-week washout pe-
riod, the subjects received the opposite test food for an 
additional 6 weeks.
Written informed consent was obtained from the 
participants before the initial screening visit and be-
fore randomization. The study protocol was approved 
by the institutional review boards of Hospital das Clí-
nicas, University of São Paulo Medical School, and of 
the Federal University of Piauí.
The participants of this study were men (30 to 70 
years of age) and postmenopausal women (45 to 70 
years of age) with mild or moderate hypercholesterole-
mia. The inclusion criterion was LDL-C concentration 
≥ 160 and ≤ 190 mg/dL. The exclusion criteria were: 
lipid-altering drug therapy (an at least 8-week was-
hout); CHD or its equivalent as defined by the NCEP 
lípidos séricos pro-aterogénicas y apoB en sujetos con 
hipercolesterolemia moderada, de manera similar a lo 
observado en un trabajo previo con los animales.
(Nutr Hosp. 2015;31:1611-1619)
DOI:10.3305/nh.2015.31.4.8457
Palabras clave: Caupi. Proteínas de plantas. Colesterol. 
Apolipoproteínas. Inflamación.
proatherogenic serum lipids and apoB in subjects with 
moderate hypercholesterolemia, similar to what was 
observed in a previous studies on animals.
(Nutr Hosp. 2015;31:1611-1619)
DOI:10.3305/nh.2015.31.4.8457
Key words: Cowpea. Plant proteins. Cholesterol. Apoli-
poproteins. Inflammation.
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ATP-III2; uncontrolled hypertension (systolic blood 
pressure >  160  mm  Hg or diastolic blood pressure 
> 100 mm Hg); significant endocrine (including diabe-
tes mellitus and familial hypercholesterolemia), hepa-
tic, renal, pancreatic, eating, and gastrointestinal disor-
ders; clinically significant laboratory results including, 
but not limited to, plasma triglycerides ≥ 400 mg/dL 
and fasting glucose ≥ 126 mg/dL; extreme dietary ha-
bits; body mass index (BMI) > 35 kg/m2; use of wei-
ght-loss medications or products; consumption of > 14 
alcoholic drinks per week, and hormone replacement 
therapy within 6 months prior to the screening visit 
and throughout the study. The subjects were recrui-
ted during routine outpatient visits to the cardiology, 
gynecology and endocrine clinics of Hospital Getúlio 
Vargas and Centro Integrado Lineu Araújo, Teresina, 
Piauí, Brazil, between May and October 2010. The 
state of menopause was assumed if no vaginal blee-
ding had occurred in the last 12 months preceding the 
study. Functional foods or dietary supplements expec-
ted to alter lipid metabolism were not allowed after 
screening. The participants were advised to maintain 
their usual life and nutrition habits, to minimize diffe-
rences in daily energy intake, to maintain their body 
weight, and to avoid the use of lipid-lowering drugs 
throughout the study. The physical characteristics and 
nutrient intake of the subjects were documented.
Study participants 
The participants of this study were men (30 to 70 
years of age) and postmenopausal women (45 to 70 
years of age) with mild or moderate hypercholesterole-
mia. The inclusion criterion was LDL-C concentration 
≥ 160 and ≤ 190 mg/dL. The exclusion criteria were: 
lipid-altering drug therapy (an at least 8-week was-
hout); CHD or its equivalent as defined by the NCEP 
ATP-III2; uncontrolled hypertension (systolic blood 
pressure >  160  mm  Hg or diastolic blood pressure 
> 100 mm Hg); significant endocrine (including diabe-
tes mellitus and familial hypercholesterolemia), hepa-
tic, renal, pancreatic, eating, and gastrointestinal disor-
ders; clinically significant laboratory results including, 
but not limited to, plasma triglycerides ≥ 400 mg/dL 
and fasting glucose ≥ 126 mg/dL; extreme dietary ha-
bits; body mass index (BMI) > 35 kg/m2; use of wei-
ght-loss medications or products; consumption of > 14 
alcoholic drinks per week, and hormone replacement 
therapy within 6 months prior to the screening visit 
and throughout the study. The subjects were recrui-
ted during routine outpatient visits to the cardiology, 
gynecology and endocrine clinics of Hospital Getúlio 
Vargas and Centro Integrado Lineu Araújo, Teresina, 
Piauí, Brazil, between May and October 2010. The 
state of menopause was assumed if no vaginal blee-
ding had occurred in the last 12 months preceding the 
study. Functional foods or dietary supplements expec-
ted to alter lipid metabolism were not allowed after 
screening. The participants were advised to maintain 
their usual life and nutrition habits, to minimize diffe-
rences in daily energy intake, to maintain their body 
weight, and to avoid the use of lipid-lowering drugs 
throughout the study. The physical characteristics and 
nutrient intake of the subjects were documented. 
Test products and intervention 
The treatments consisted of a CPI and casein (con-
trol) beverage powder (Linea Sucralose, Anapolis, 
Brazil) in two 30-g packets/day. The subjects were as-
ked to incorporate two servings/day into their normal 
diet during the intervention period, one during break-
fast and one in the late afternoon or early evening. Du-
ring the CPI treatment phase (CPI shake), the subjects 
drank shakes similar to those consumed during the 
control phase (control shake: 25 g casein/day), except 
that the treatment phase products were formulated with 
cowpea protein (25 g CPI/day). The CPI was produced 
by Bremil Arroio do Meio Ltda. (Rio Grande do Sul, 
Brazil) by alkaline extraction of protein from defatted 
cowpea flour, centrifugation (10,000 x g) and acid (pH 
4.5) precipitation of the protein, followed by centrifu-
gation and spray drying of the precipitate14. The CPI 
shake had an average nutrient content of 108.3  kcal 
energy, 12.6 g protein, 12.1 g carbohydrate, 0.4 g fat, 
and 337.2 mg calcium. The casein shake had an ave-
rage nutrient content of 106.01  kcal energy, 14.1  g 
protein, 10.1 g carbohydrate, 0.3 g fat, and 385.9 mg 
calcium. Two flavors were offered to the volunteers: 
strawberry and mixed fruit. The subjects perceived the 
CPI and control shakes as identical in appearance and 
taste. To ensure blinding, the study participants recei-
ved their supplies in packages labeled with three di-
gits without any other information. This code was kept 
secret from all participants, including the researchers. 
In the middle of each treatment period, staff contacted 
the participants by telephone to encourage compliance 
with consumption of the study product.
Laboratory tests 
Blood samples (20 mL) were collected into tubes 
without anticoagulant after a 12-hour fast. The samples 
were immediately centrifuged at 1,100 x g for 15 mi-
nutes at 4 °C, serum was separated, and aliquots were 
stored at -80 °C until the time of analysis. Serum total 
cholesterol, triglycerides, and direct HDL-cholesterol 
(HDL-C) were measured by automated enzymatic me-
thods using Roche Diagnostic kits (Sao Paulo, Brazil). 
LDL-C concentration (mg/dL) was calculated accor-
ding to the Friedewald formula15 for triglyceride levels 
< 400 mg/dL. NonHDL-cholesterol (NonHDL-C) was 
calculated by subtracting HDLC from total cholesterol. 
Apolipoproteins (apoAI and apoB) were measured by 
automated standardized immunoassays (Roche Diag-
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nostics). Soluble adhesion molecule concentrations 
(sICAM1 and sVCAM1) were analyzed in duplicate 
in a single run using enzyme-linked immunosorbent 
assays (R & D Systems®, Minneapolis, MN, USA). 
Serum highly sensitive CRP concentrations were as-
sessed by turbidimetry (BioTécnica®, Sao Paulo, Bra-
zil) in a Cobas Mira Plus (Roche®) device according 
to manufacturer instructions. Glucose concentrations 
were measured by an enzymatic colorimetric method 
(Labtest, Belo Horizonte, Brazil).
Clinical and nutritional evaluation 
A baseline questionnaire was administered to record 
demographic and lifestyle characteristics and medical 
history. Body weight, height and waist circumferen-
ce were measured at baseline and at the end of each 
experimental period. BMI (kg/m2) was calculated as 
body weight/height2. Nutritional evaluation was per-
formed by the application of three 24-h dietary recalls 
at baseline and at the end of each phase. Dietary com-
position was analyzed using the NutWin® nutrition su-
pport program (v. 1.5)16. Side effects and compliance 
were assessed using a symptom questionnaire, counts 
of returned unconsumed packets, and self-reported su-
pplement use.
Statistical analysis 
Data are reported as the mean ± standard error of 
the mean (SEM), except for CRP, sVCAM-1 and sI-
CAM-1 which are expressed as means (95% confi-
dence interval). Differences in serum lipids, apolipo-
proteins, inflammatory biomarkers, anthropometric 
measures and food consumption as a function of type 
and order of the ingested shakes were evaluated by 
three-factor repeated measures ANOVA, assuming 
structured correlations of symmetric components be-
tween assessments. When statistically significant re-
sults were obtained, multiple comparisons were per-
formed by the Bonferroni method17 to verify which 
treatment was the most significant and whether the 
ingestion order influenced the results. The difference 
in each lipid and apolipoprotein concentration (delta: 
end - beginning) was calculated for each shake. The 
percent variation [delta  %:  (end beginning)/begin-
ning] was also calculated for lipids and apolipopro-
teins and related to each shake and ingestion order. 
The mean variations in each parameter according to 
shake are reported with their standard error, adopting 
a level of significance of 5%. The sample size was 
based on a predicted 21 mg/dL reduction in total cho-
lesterol after consumption of CPI. The variability in 
the outcome parameter was estimated at 40  mg/dL 
and the standardized effect size was 0.52. The adop-
ted statistical power was 80% (β = 0.20, α = 0.05) 
and the calculated sample size was 35 subjects. All 
calculations were performed using the SAS software 
(Cary, NC, USA)18.
Results
Forty-four subjects were initially assigned to the two 
groups for 6 weeks, including 23 in the casein group 
and 21 in the CPI group. After a 4-week washout pe-
riod, the subjects received the opposite test food for an 
additional 6 weeks.
The CPI and casein shakes were well accepted by 
most participants. Among the 44 subjects who agreed 
to participate in the study, only six (13%) did not com-
plete it. The reasons for study drop out were: missing 
some appointments (n =1); illness (n = 2); changes in 
the clinical exams (weight gain) (n = 1), and failure 
to consume the products (n = 2). Table I shows the 
baseline clinical and laboratory characteristics of the 
subjects who completed the study (n = 38).
Table II shows the anthropometric characteristics 
and daily dietary nutrient intake based on 24-h recalls 
before and after consumption of the casein and CPI 
shakes. The interventions did not result in significant 
changes in body weight, BMI or waist circumference 
during the study. The subjects consumed similar daily 
amounts of food during the study period. There were no 
significant differences in energy, macronutrient or satu-
rated, monounsaturated and polyunsaturated fat intake.
Table III shows the concentrations of serum lipids 
and apolipoproteins before and after consumption 
of the test shakes, as well as the percent changes in 
each phase. The consumption of CPI resulted in a de-
crease in total cholesterol, LDL-C, nonHDL-C, and 
apoB concentrations (all p values <  0.001). There 
were significant, although small, increases in HDL-C 
(p = 0.047). No significant differences were observed 
in triglyceride or apoAI concentrations. 
Table IV shows the mean net changes in serum li-
pids and apolipoproteins when consumption of ca-
sein was crossed over to CPI or vice-versa after the 
washout period. A significant net reduction in serum 
total cholesterol, LDL-C, non-HDL-C, and apoB was 
observed for CPI consumption, irrespective of inges-
tion order (all p values < 0.001). In contrast, HDL-C 
showed a net increase of 5.6% (p = 0.044).
The comparison of inflammatory and endothelial 
dysfunction biomarkers between the CPI and casein 
shakes is shown in table V. No significant changes in 
these biomarkers were observed during any phase of 
the study.
The main side effects observed after the consump-
tion of cowpea protein were flatulence (10.5 %, n = 
4), obstipation (7.9 %, n = 3), and an increase in stool 
softening (5.3 %, n = 2). The side effects observed af-
ter the consumption of casein protein were flatulence 
(7.9 %, n = 3), obstipation (2.6 %, n = 1) and an increa-
se in stool softening (5.3 %, n = 2). No patient dropped 
out of the study due to side effects. 
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Table I  
Baseline clinical and laboratory characteristics of the study participants (n = 38)
Characteristic Average
Age, years 57.0 (1.7)
Women, n (%) 32 (84 %)
Current smoking, n (%) 3 (7.9 %)
Alcohol drinking, n (%) 9 (23.7 %)
Body weight, kg 66.7 (2.3)
Body mass index, kg/m2 27.3 (0.6)
Waist circumference, cm 88.8 (1.6)
Total cholesterol, mg/dL 270.6 (21.5)
LDL-C, mg/dL 182.6 (15.9)
HDL-C, mg/dL 56.4 (9.8)
Triglycerides, mg/dL 157.3 (63.3)
Non-HDL-C, mg/dL 214.2 (19.9)
Apolipoprotein B, mg/dL 131.0 (3.0)
Apolipoprotein A-I, mg/dL 151.0 (3.0)
Fasting glucose, mg/dL 101.6 (12.6)
CRP, mg/L 1.62 (1.24, 2.00)
Soluble VCAM-1, ng/mL 231.3 (203.9, 258.7))
Soluble ICAM-1, ng/mL 117.0 (101.4, 132.6)
1Values are means (SEM), except for C-reactive protein (CRP), soluble vascular adhesion molecule 1 (VCAM-1), and soluble intercellular 
adhesion molecule 1 (ICAM-1) which are reported as means (95% confidence interval).
Discussion
This is the first study that investigated and showed 
favorable effects of CPI in reducing serum proathe-
rogenic lipids and apoB in moderate hypercholeste-
rolemic adults. Although Brazil is one of the largest 
producers of cowpea in the world19, most studies in-
vestigating the effects of vegetable protein on plasma 
lipids and biomarkers have used soy protein12, 20-21. Our 
results reproduced the favorable effects of cowpea 
protein on plasma lipids demonstrated in an animal 
model13. Nevertheless, the consumption of CPI did 
not change biomarkers of subclinical inflammation or 
endothelial dysfunction. The consumption of CPI was 
well tolerated.
The most remarkable findings of this study were 
the consistent and robust reductions in LDL-C and 
nonHDL-C induced by the consumption of 25 g/day 
of cowpea protein. Additionally, a reduction in apoB 
concentrations was observed, suggesting that CPI con-
sumption reduced not only cholesterol content, but 
also the concentration of proatherogenic serum lipo-
proteins. The present findings are similar to the effects 
of soy protein reported in humans22, 23. Cowpea protein 
also exerted favorable effects on HDL-C, although to 
a lesser extent. 
The relative and absolute changes in proatheroge-
nic serum lipids and apolipoproteins observed in the 
present study can be considered robust when these fin-
dings are compared to the results of three meta-analy-
ses that evaluated the effect of soy protein supplemen-
tation on serum lipids. Anderson et al.20 showed that an 
average soy protein intake of 47 g per day was associa-
ted with the following net changes in serum lipid con-
centrations compared to the concentrations achieved 
with the control diet: a 9.3% decrease in total choleste-
rol and a 12.9 % decrease in LDL-C. Reynolds et al.21 
observed an overall pooled net absolute effect of soy 
protein supplementation on serum lipids of 5.3  mg/
dL for total cholesterol, 4.2  mg/dL for LDL-C, and 
0.8 mg/dL for HDL-C. Anderson and Bush24 showed 
that soy protein intake was associated with net reduc-
tions of 5.5% and 4.2% in serum LDL-C in parallel 
and crossover studies, respectively.
Reductions in LDL-C concentrations are one of the 
most powerful strategies to decrease CVD risk. The ave-
rage reduction of 33 mg/dL in this lipid fraction found 
in the present study is of significant clinical importance. 
A recent meta-analysis including 170,000 subjects who 
received lipid-lowering therapy with statins showed that 
each 40 mg/dL decrease in LDL-C reduces the risk of 
major atherosclerotic events by 22%25. Furthermore, 
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Table II  
Anthropometric characteristics and nutrient intake before and after consumption of the  
cowpea protein isolate and casein shakes (n = 38)
Treatment group
Cowpea protein isolate Casein
Baseline Week 6 Baseline Week 6 P-value
Anthropometric variable
BMI, kg/m2 27.3 (0.6) 27.2 (0.6) 27.1 (0.6) 27.2 (0.6) 0.91
Body weight, kg 66.9 (2.3) 66.7 (2.4) 66.3 (2.3) 66.6 (2.3) 0.73
Waist circumference, cm 88.4 (1.5) 88.5 (1.6) 88.2 (1.5) 88.3 (1.5) 0.67
Nutrient intake
Energy, kcal 1,344.6(95.6) 1,400.3 (70.8) 1,388.3(84.55) 1,370.1(89.4) 0.47
Carbohydrate, g 198.5 (16.3) 181.8 (9.6) 184.7 (14.1) 171.1 (14.1) 0.08
Protein, g 71.7 (5.4) 92.3 (6.9) 80.4 (6.7) 90.7 (5.6) 0.73
Fat, g 34.8 (3.7) 33.7 (3.2) 41.9 (5.8) 34.5 (3.1) 0.34
Saturated fat, g 9.3 (1.2) 8.2 (1.0) 9.4 (0.9) 8.3 (0.9) 0.85
Polyunsaturated fat, g 7.3 (0.8) 6.7 (0.6) 7.0 (0.7) 7.2 (0.7) 0.18
Monounsaturated fat, g 10.3 (2.0) 8.7 (1.0) 9,1 (0,8) 9.4 (1.2) 0.50
Cholesterol, mg 138.2 (22.8) 187.9 (22.7) 178,6 (16,6) 165.7 (40.3) 0.01
Fiber, g 17.1 (2.2) 11.7 (1.2) 14,3 (1,8) 11.8 (1.6) 0.05
1Values are means (SEM). The P-value corresponds to the difference between treatments using repeated measures ANOVA.
Table III 
Serum lipid and apolipoprotein concentrations before and after consumption of the  
cowpea protein isolate and casein shakes (n = 38)1
Treatment group
Cowpea protein isolate Casein
Biomarker Baseline Week 6 Baseline Week 6 P-value
TC, mg/dL 264.4 (3.8) 232.3 (4.4) 265.4(4.2) 254.3 (4.5) < 0.001
TC, % change -12.1 (1.1) -3.7 (1.8) < 0.001
LDL-C, mg/dL 174.9 (3.0) 141.9 (3.6) 174.5 (3.2) 165.0 (3.6) < 0.001
LDL-C, % change -18.9 (1.5) -4.5 (2.5) < 0.001
HDL-C, mg/dL 56.0 (1.4) 57.3 (1.5) 56.6 (1.6) 54.6 (1.5) 0.041
HDL-C, % change 2.7 (2.1) - 2.8 (1.9) 0.047
TG, mg/dL 166.3(11.1) 163.5(14.3) 165.5(8.8) 173.0(9.7) 0.406
TG, % change 1.3 (5.5) 8.6 (5.7) 0.358
Non-HDL-C, mg/dL 208.3(3.5) 175.0(4.2) 208.8(3.9) 199.8(4.3) < 0.001
Non-HDL-C, % change -16.0 (1.5) - 3.8 (2.0) < 0.001
ApoA-I, mg/dL 153.0 (3.0) 153.0 (3.0) 151.0 (3.0) 149.0 (4.0) 0.509
ApoA-I, % change 0.6 (1.6) - 1.3 (1.3) 0.349
ApoB, mg/dL 131.0 (3.0) 112.0( 3.0) 128.0 (2.0) 125.0 (3.0) < 0.001
ApoB, % change -14.0 (1.5) - 2.2 (2.1) < 0.001
1 Values are means (SEM). The P-value corresponds to the difference between baselines values and values obtained after 6 weeks using repeated 
measures ANOVA. TC: total cholesterol; TG: triglycerides.
021_8457 Proteina caupi reduce las concentraciones de LDL.indd   1616 27/02/15   08:41
1617Nutr Hosp. 2015;31(4):1611-1619Cowpea protein reduces LDL-cholesterol 
and apolipoprotein B concentrations, but 
does not improve biomarkers ...
Table IV 
Net (mg/dL) and percent (%) changes in serum lipid and apolipoprotein concentrations in subjects ingesting cowpea 
protein isolate compared to those consuming casein (n = 38)1
Biomarker Cowpea protein isolate vs casein P-value
Total cholesterol, mg/dL -21.05 (4.40) < 0.001
Total cholesterol, % -8.4 (1.7) < 0.001
LDL-C, mg/dL -23.53 (5.40) < 0.001
LDL-C, % -14.4 (2.5) < 0.001
HDL-C, mg/dL 3.24 (1.56) 0.044
HDL-C, % 5.6 (2.7) 0.043
Non-HDL-C, mg/dL -24.29 (4.27) < 0.001
Non-HDL-C, % -12.1 (2.1) < 0.0001
ApoB, mg/dL -15.55 (3.43) < 0.001
ApoB, % -11.7 (2.6) < 0.001
1Variations in the parameters that differed between treatments. Multiple comparisons by the Bonferroni method (p < 0.05). Values are means 
(SEM).
Table V 
Serum levels of C-reactive protein (mg/L), soluble intercellular adhesion molecule 1 (ng/mL) and soluble vascular cell 
adhesion molecule 1 (ng/mL) before and after consumption of the cowpea protein isolate and casein shakes (n = 38)1
Treatment group
Cowpea protein isolate Casein
Baseline Week 6 Baseline Week 6 P-value
CRP 1.96 (1.35, 2.57) 2.43 (1.68, 3.18) 1.91 (1.49, 2.33) 2.27 (1.71, 2.83) 0.838
sVCAM-1 246.1 (220.5, 271.7) 252.9 (219.7, 286.1) 246.3 (215.5, 277.1) 266.5 (234.2, 298.9) 0.401
sICAM-1 127.3 (111.3, 143.5) 137.9 (117.7, 158.2) 123.5 (105.1, 141.8) 138.6 (116.2, 161.0) 0.644
CRP: C reactive protein; sVCAM-1: soluble vascular cell adhesion molecule 1; sICAM-1: soluble intercellular adhesion molecule 1. 1The 
P-value corresponds to the difference between baselines values and values obtained after 6 weeks using repeated measures ANOVA. Data are 
expressed as means (95% confidence interval).
there is evidence that each 1% decline in LDL-C over a 
period of 5 years results in a 1% reduction in CVD risk26. 
Non-HDL-C is an independent marker of CHD and 
stroke risk27. Evidence from a meta-analysis including 
more than 130,000 subjects indicates that a reduction 
in non-HDL-C exerts favorable effects on CVD risk 
even after adjustment for changes in LDL-C. These 
studies included different lipid-lowering strategies, 
such as diet, and showed that each 1% reduction in 
non-HDL-C decreased the risk of CVD by 1%27. The-
refore, the reductions in non-HDL-C and apoB con-
centrations achieved with CPI in the present study may 
also be of clinical importance. 
Healthy lifestyles, including dietary interventions 
that reduce serum cholesterol, are recommended as 
population strategies to reduce CVD risk2. The pre-
sent study suggests that the consumption of cowpea 
protein, which can favorably modify the lipid profile 
and because it is widely available, may be an impor-
tant strategy to reduce cholesterol and CVD risk in the 
population. 
The cholesterol-lowering properties of soybeans 
have been hypothesized to reside in certain peptides 
or peptide fractions present in soy28. Like soy protein, 
cowpea protein may exert a protective effect against 
CVD by lowering LDL-C concentration. Cho et al.28 
reported that hydrolyzed soybean protein exhibited 
hypocholesterolemic effects by stimulating hepatic 
LDL receptor expression. In the case of cowpea pro-
tein which has shown marked effects on lipid parame-
ters in both humans and experimental animals13, pep-
tides may be formed during processing and digestion. 
Marques et al.29 identified peptides in the protein iso-
late from raw bean with a molecular mass of less than 
3 kDa, which reduced the reaction velocity of 3-hy-
droxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase by 89%. HMG-CoA reductase is the rate-limi-
ting enzyme in hepatic cholesterol synthesis. For this 
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reason, this enzyme is the target of several drugs used 
to control high cholesterol levels30. However, other 
mechanisms could be involved in the hypocholestero-
lemic effect of cowpea protein. 
Despite favorable effects on proatherogenic lipids 
and apoB, CPI did not affect the inflammatory and 
endothelial dysfunction biomarkers studied (CRP, sI-
CAM1 and sVCAM1) when compared to control (ca-
sein). Similarly, recently published study showed that 
supplementation with soy or isolated soy protein does 
not alter CRP concentrations in humans31. 
The effects of legumes on biomarkers of inflam-
mation and endothelial dysfunction are still un-
clear31-34. One study conducted over a period of 3 years 
on monkeys receiving 19% of calories derived from 
soy protein found a significant reduction in VCAM1 
concentrations35. These controversial results regarding 
the effect of legumes on biomarkers of endothelial 
dysfunction suggest that these outcomes are influen-
ced by other factors such as study duration and protein 
dose used. No effects of legume proteins on adhesion 
molecules were found in the present study and in three 
previous reports31,33,34. In two of these studies, the du-
ration of the protocols was relatively short (only 6 and 
8 weeks) and 26 to 40 g soy protein was offered31,33. In 
the other study34, the protocol had a duration of 6 mon-
ths, but only 15 g soy protein was offered. Long-term 
exposure associated with a representative amount of 
plant protein may be necessary to observe reductions 
in the serum concentrations of these biomarkers. These 
studies incorporated a similar amount of about 25 g of 
legume protein. A larger amount of plant protein may 
be necessary to observe some effect on adhesion mo-
lecules. Furthermore, the sample size of our study may 
have been too small to detect significant changes in 
biomarkers other than total cholesterol and its biolo-
gically related parameters (LDL-C, nonHDL-C, and 
apoB). In view of these limitations, we cannot rule out 
possible effects of cowpea protein on biomarkers of 
inflammation and endothelial dysfunction.
Despite the favorable effects of cowpea protein ob-
served in the present study, further investigation is nee-
ded to confirm its effects on the blood lipid profile of 
humans. Furthermore, longer follow-up studies using 
different doses of CPI and including subjects with di-
fferent degrees of dyslipidemia should be conducted. 
In conclusion, in this proof-of-concept study, 
cowpea protein significantly reduced proatherogenic 
lipids and apoB in moderately dyslipidemic subjects. 
In view of its wide availability19, cowpea protein may 
be an alternative to soy protein to reduce cholesterol 
levels and possibly to prevent CVD.
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